From a clinical perspective, our data provides the preclinical rationale for the initiation of a phase I study of RALB inhibition with novel multivalent TRAIL receptor 2/DR5 agonists (eg. MEDI3039)58,59 in KRASMT CRIS-B CRC with high expression levels of RALB. Here, RALB is linked to colorectal carcinoma.